Equally, injection of aAPC particles loaded with both IL-2 and anti-CTLA-4 outperformed conventional single-release aAPCs, efficiently promoted sustained ICI and IL-2 release as well as antigen-specific T cell activation and expansion, and inhibited tumor growth in a murine melanoma model [110]. Here, IL2 is linked to melanoma.